GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus , an insulin glargine injection and Sanofi's most widely ...

The company specified that patients will be able to use the coupon regardless of their health insurance coverage. The announcement comes more than six months after Sanofi pledged to slash the list ...

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...